1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017


Delayed Xetra  -  11:44 2022-08-05 am EDT
53.28 EUR   -6.98%
08/05U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer
08/05Bayer CropScience Limited reports Q1 Results for FY 2022-23
08/05BAYER AG : Credit Suisse reiterates its Neutral rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer : Darolutamide plus androgen deprivation therapy and docetaxel demonstrates consistent overall survival benefits across various patient segments in metastatic hormone-sensitive prostate cancer

07/04/2022 | 03:03am EDT
Monday - July 4, 2022
Bitte JavaScript aktivieren / Please enable JavaScript

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

1 Bertrand T et al, Overall Survival with Darolutamide Versus Placebo in Combination with Androgen-Deprivation Therapy and Docetaxel by Stratification Factors in the Phase 3 ARASENS Trial. Presented at EAU22 July 2022
2 Smith R et al. N Engl J Med 2022; 386:1132-1142
3Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21660. Accessed June 2022

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.


Bayer AG published this content on 04 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 July 2022 07:02:07 UTC.

© Publicnow 2022
All news about BAYER AG
08/05U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination..
08/05Bayer CropScience Limited reports Q1 Results for FY 2022-23
08/05BAYER AG : Credit Suisse reiterates its Neutral rating
08/05BAYER AG : Berenberg reiterates its Buy rating
08/05BAYER AG : Deutsche Bank remains its Buy rating
08/04Healthcare Shares Slip Amid Deal News -- Healthcare Roundup
08/04European Bourses Edge Up; Bank of England Raises Rates, Expects 13% Inflation
08/04Bayer CEO Says Arbitration Court Close to Ruling on BASF Overpayment Claims
08/04GLOBAL MARKETS LIVE : Bayer, Merck, eBay, MetLife, Eli Lilly...
08/04Bayer says arbitration ruling over BASF claims is imminent
More news
Analyst Recommendations on BAYER AG
More recommendations
Sales 2022 49 200 M 49 970 M 49 970 M
Net income 2022 4 899 M 4 975 M 4 975 M
Net Debt 2022 32 159 M 32 662 M 32 662 M
P/E ratio 2022 10,8x
Yield 2022 4,19%
Capitalization 52 344 M 53 162 M 53 162 M
EV / Sales 2022 1,72x
EV / Sales 2023 1,67x
Nbr of Employees 101 914
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 24
Last Close Price 53,28 €
Average target price 77,91 €
Spread / Average Target 46,2%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG13.36%53 162
JOHNSON & JOHNSON0.02%449 879
PFIZER, INC.-15.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.2.60%244 068